Clinical Trials
40 trialsNCT03289962 2026-05-29
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.
Phase 1 Completed
NCT06885424 2026-05-20
DESCENT-1
A2 Biotherapeutics Inc.
Enrolling by invitation
NCT07244835 2026-05-13
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
Phase 1 Recruiting
NCT06239194 2026-05-06
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting
NCT05520099 2026-04-29
ELEPHAS-02
Elephas
Active not recruiting
NCT06444815 2026-04-07
STEALTH-001
KaliVir Immunotherapeutics
Phase 1 Recruiting
NCT06546553 2026-02-23
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Pfizer
Phase 1 Terminated
NCT04485013 2026-02-18
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Phase 1 Recruiting
NCT05070247 2026-01-22
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Terminated
NCT05366881 2026-01-20
CAMPERR
Adela, Inc
Recruiting
NCT07341737 2026-01-15
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
Phase 1/2 Not yet recruiting
NCT07327489 2026-01-08
ELEPHAS-05
Elephas
Recruiting
NCT05544929 2026-01-06
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Phase 1 Active not recruiting
NCT03452774 2025-10-28
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Recruiting
NCT06682793 2025-09-09
DENALI-1
A2 Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT05864144 2025-08-15
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Phase 1/2 Active not recruiting
NCT04825834 2025-08-08
DELFI-L101
Delfi Diagnostics Inc.
Completed
NCT03175224 2025-06-27
SPARTA
Apollomics Inc.
Phase 2 Recruiting
NCT05704985 2025-05-29
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
Phase 1 Active not recruiting
NCT05179824 2025-05-06
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Active not recruiting
NCT04383210 2025-04-03
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
Phase 2 Terminated
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT03809624 2024-10-23
PDL1x41BB
Inhibrx Biosciences, Inc
Phase 1 Terminated
NCT03329950 2024-03-28
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
Phase 1 Completed
NCT03454451 2023-12-21
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
Phase 1 Completed
NCT05961111 2023-07-27
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
Shanghai Yunying Medical Technology
Phase EARLY_PHASE1 Recruiting
NCT05708950 2023-07-13
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
Phase 1/2 Unknown
NCT04430842 2023-01-18
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
Phase 1 Completed
NCT02315066 2022-04-21
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Pfizer
Phase 1 Completed
NCT03319459 2021-11-22
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
NCT03896958 2020-12-04
PIONEER
SpeciCare
Unknown
NCT02223052 2020-05-12
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1 Completed
NCT00896454 2018-10-17
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Amgen
Phase 2 Completed
NCT02543645 2018-04-30
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Celldex Therapeutics
Phase 1 Terminated
NCT02262455 2017-02-13
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Santa Maria Biotherapeutics
Phase 1 Completed
NCT00413075 2015-07-08
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Valerio Therapeutics
Phase 1 Completed
NCT00413322 2015-07-08
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Valerio Therapeutics
Phase 1 Completed
NCT00496860 2013-07-22
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
Altor BioScience
Phase 1 Completed
NCT00513851 2011-09-27
Phase 1 Study of OSI-930 in Cancer Patients
Astellas Pharma Inc
Phase 1 Completed
NCT00120939 2009-04-03
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
Pharmacyclics LLC.
Phase 1 Completed